QLife

Bolag

QLife

Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret beläget i Helsingborg.

Snabbfakta

Ticker
QLIFE
Börs
First North Stockholm
Sektor
Hälsovård
Bransch
Medicinteknik
Webbplats
Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
QLIFE

Qlife Secures U.S. Patent Approval for Core Egoo Platform Technology, Strengthening Global Partnering Position

Qlife Holding AB ("Qlife" or the "Company") today announces that the United States Patent and Trademark Office (USPTO) has approved the Company's U.S. patent application covering core Egoo platform technology for issuance. The approval establishes patent protection for key elements of the platform in the United States and further strengthens Qlife's global intellectual property position.

QLIFE

Qlife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch

Qlife Holding AB ("Qlife" or the "Company") a first mover in clinical-grade home diagnostics, announces publication of the clinical study for PKU children and adolescents under 18 years of age. The study, led by Professor Anita MacDonald at Birmingham Women's and Children's NHS Foundation Trust, demonstrated solid validation of the Egoo system for home testing in this setting. The outcome represents a significant milestone as Qlife prepares for its upcoming CE-IVDR submission and subsequent market launch. The Egoo PHE System, the first application of the Egoo Health platform, enables essential laboratory blood testing for this rare condition to be performed in patients' homes. This innovation will simplify disease management and enhance quality of life for affected individuals.

QLIFE

Qlife Holding AB: Update on the reverse takeover process - "Red Chip" structure will not be approved by Nasdaq - other structures are pursued

Qlife Holding AB ("Qlife" or "the Company") and Hipro Biotechnology Co., Ltd. ("Hipro") are working on the planned reverse takeover, as announced in press releases on 5 June 2025 and 5 October 2025. Hipro is currently working on obtaining the required shareholder approvals to be able to carry out the reverse takeover. The companies' legal advisors in China have recommended a transaction structure for the reverse takeover called a "Red Chip" structure, which means that Qlife is to acquire Hipro through overseas entities. Nasdaq Stockholm AB ("Nasdaq") has now informed that the Company will not be approved for continued listing if the Company carries out the "Red Chip" structure. The reason for this is that such structure does not meet Nasdaq's requirements for listing at Nasdaq First North and that in order for Nasdaq to approve it, they would likely need to consider certain changes to their rules and processes.

Ackumulerad insynshandel (SEK)

Inga rapporterade insynsköp eller försäljningar under perioden

Blankning (%)

Inga rapporterade blankningspositioner under perioden